Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Nanobiotix ( (NBTX) ) is now available.
On May 21, 2025, Nanobiotix announced significant progress in its first quarter 2025 operational and financial update. The company dosed its first patient in the CONVERGE study, a Phase 2 trial for stage 3 unresectable non-small cell lung cancer, and presented promising data at the European Lung Cancer Conference. Financially, Nanobiotix strengthened its position by amending its global licensing agreement for JNJ-1900 (NBTXR3), extending its cash runway into mid-2026 and reducing operational cash burn. These developments are expected to bolster Nanobiotix’s market positioning and stakeholder confidence.
The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The overall stock score of 43 reflects Nanobiotix’s substantial financial challenges, including declining revenues, negative profitability, and a high leverage ratio. While the strategic partnership with JNJ offers potential future milestones and an extended cash runway, current financial performance and valuation metrics remain under significant pressure. Technical indicators show some positive momentum, but overall stock performance is hindered by underlying financial instability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company specializing in nanotherapeutic approaches to improve treatment outcomes for cancer and other diseases. Founded in 2003 and headquartered in Paris, France, the company is listed on Euronext Paris and the Nasdaq Global Select Market. Nanobiotix focuses on oncology, bioavailability, biodistribution, and central nervous system disorders, with over 25 patent families.
Average Trading Volume: 11,576
Technical Sentiment Signal: Sell
Current Market Cap: $186.6M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.